C-RAD received an order of three Catalyst ™ Systems from Kaiser Franz Josef Spital in Vienna, Austria.
Kaiser Franz Josef Spital is an advanced radiation therapy site in the center of Vienna. The main focus for our partner is to use Catalyst ™ for improving the setup of patients and monitoring them while treatment. For advanced treatment techniques the precise setup is one key factor to ensure a successful treatment. The radiation therapy department has been equipped with two new Varian TrueBeam® machines recently. In combination with C-RAD Catalyst ™ patients enjoy a treatment in a cutting edge radiation therapy facility.
Dr. Harald Krauss, Head of Physics KFJ Spital:
“As a routine radiotherapy department with a lot of patients, we strive to deliver highest treatment quality in short time slots.
Advanced treatment techniques such as IMRT, which we have implemented in the year 2000 are performed mainly in the head and neck and pelvic region. With approximately 50% of all patients breast is the largest patient group treated at our institute. Sometimes it is a challenge to set those patients up on the treatment machines.
We are expecting and we are confident that Catalyst will help us not only to optimize the setup processes of all conformal and high-precision treatments, but also improve treatment quality with its monitoring capabilities.“
Tim Thurn, CEO, C-RAD AB:
“We have started to present C-RAD technology to the Austrian customers last year. We saw huge interest in this advanced market. Kaiser-Franz Josef Spital won the race to be the first site in Austria. We are looking forward to expand our business in this market. Further projects are ongoing.”
About C-RAD
C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 29 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company’s first product, the C-RAD Sentinel TM, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has invested in 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier.
For more information on C-RAD, please visit www.c-rad.com .
For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666931, E-mail investors@c-rad.com
